+1 (855) PLE.XISION (753.9474) info@plexision.com

Limitations and Emerging Needs

You are here

  • To maximize benefit and minimize risk, it is critical to know whether a particular checkpoint inhibitor is effective in augmenting the anti-tumor immune response in a given patient.

  • To determine whether a checkpoint inhibitor may be effective, immune staining is used to determine whether its target is expressed by the tumor. To determine whether a tumor is antigenic and may therefore elicit an immune response, tumor DNA sequencing is used to identify novel antigens or neoantigens, which are absent in normal tissues.

  • These methods characterize the tumor phenotype, and are not foolproof. Several checkpoints act simultaneously to modulate anti-tumor immune responses. For this reason, the dominant checkpoint by which a tumor escapes immune attack may not be targeted by a particular inhibitor. Further, whether the immune system ‘sees’ the tumor as antigenic, and whether the anti-tumor response is enhanced by a checkpoint inhibitor cannot be determined by phenotypic characterization.